[Postoperative follow-up of gastric adenocarcinoma with neoplastic markers and 18-FDG-PET/TC].
BACKGROUND
The usefulness of tumour markers CEA, CA19.9 and CA72.4 in association with FDG-PET/TC were prospectively evaluated in the post-operative follow-up of gastric cancer patients.


METHODS
Fifty one consecutive patients were enrolled in a follow-up programme entailing with periodical clinical evaluations, instrumental examinations and tumour markers assay FDG-PET/TC was performed only in cases of suspected recurrence.


RESULTS
Sensitivity of CEA, CA19.9 e CA72.4 during the follow-up period was respectively: 16%, 33.3% e 50%. Overall sensitivity was 66.6%. Specificity was 100% for CEA, 93.3% for CA19.9, 100% for CA72.4, with an overall specificity of 96.2%. FDG-PET/TC had a sensitivity of 100%.


CONCLUSIONS
Tumour markers in association with FDG-PET/TC allow an early identification of recurrences after surgery, with the advantage to start chemotherapy or surgical protocols before the tumour has reached an advanced stage.
Patriti
Alberto
A
Università degli Studi di Perugia, Dipartimento di Scienze Chirurgiche, Radiologiche ed Odontostomatologiche, Sezione di Chirurgia Generale e d'Urgenza. albertopatriti@gmail.com
Graziosi
Luigina
L
Baffa
Nicodemo
N
Pacifico
Eugenio
E
Lamprini
Papaefthimiou
P
Valiani
Saverio
S
Gullà
Nino
N
Donini
Annibale
A
D000230:Adenocarcinoma / Q000276:immunology / Q000601:surgery*; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000276:immunology; D049268:Positron-Emission Tomography; D011184:Postoperative Period; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000276:immunology / Q000601:surgery*; D014057:Tomography, X-Ray Computed
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; C083825:CA-72-4 antigen; D002272:Carcinoembryonic Antigen; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18